LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Novo Nordisk A-S

Затворен

СекторЗдравеопазване

67.74 0.61

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

67.19

Максимум

68.3

Ключови измерители

By Trading Economics

Приходи

804M

29B

Продажби

-7.6B

78B

P/E

Средно за сектора

19.207

50.291

EPS

6.53

Дивидентна доходност

2.32

Марж на печалбата

37.182

Служители

77,406

EBITDA

5.9B

46B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+40.74% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.32%

2.40%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

43B

309B

Предишно отваряне

67.13

Предишно затваряне

67.74

Настроения в новините

By Acuity

80%

20%

359 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Novo Nordisk A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.05.2025 г., 11:36 ч. UTC

Топ новини

Novo Nordisk CEO to Step Down Amid Market Challenges

12.05.2025 г., 09:36 ч. UTC

Значими двигатели на пазара

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7.05.2025 г., 11:29 ч. UTC

Топ новини
Печалби
Значими двигатели на пазара

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

24.06.2025 г., 10:26 ч. UTC

Пазарно говорене

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

23.06.2025 г., 13:09 ч. UTC

Пазарно говорене

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

20.06.2025 г., 13:31 ч. UTC

Придобивния, сливания и поглъщания

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

13.06.2025 г., 11:39 ч. UTC

Пазарно говорене

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

13.06.2025 г., 10:04 ч. UTC

Пазарно говорене

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

11.06.2025 г., 09:45 ч. UTC

Пазарно говорене

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

10.06.2025 г., 13:38 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk -- WSJ

9.06.2025 г., 10:09 ч. UTC

Пазарно говорене

Novo Nordisk Valuation Presents a Good Opportunity -- Market Talk

3.06.2025 г., 15:03 ч. UTC

Придобивния, сливания и поглъщания

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29.05.2025 г., 01:00 ч. UTC

Топ новини

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20.05.2025 г., 14:08 ч. UTC

Печалби

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20.05.2025 г., 07:43 ч. UTC

Пазарно говорене

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16.05.2025 г., 18:35 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16.05.2025 г., 17:34 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16.05.2025 г., 13:42 ч. UTC

Горещи акции

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16.05.2025 г., 13:27 ч. UTC

Пазарно говорене

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16.05.2025 г., 13:15 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16.05.2025 г., 12:17 ч. UTC

Печалби

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12.05.2025 г., 22:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12.05.2025 г., 18:45 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12.05.2025 г., 12:07 ч. UTC

Пазарно говорене

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12.05.2025 г., 07:20 ч. UTC

Пазарно говорене

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7.05.2025 г., 15:13 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7.05.2025 г., 13:56 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7.05.2025 г., 13:45 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7.05.2025 г., 11:25 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7.05.2025 г., 11:18 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Novo Nordisk A-S Прогноза

Ценова цел

By TipRanks

40.74% нагоре

12-месечна прогноза

Среден 94.79 USD  40.74%

Висок 142.564 USD

Нисък 61 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Novo Nordisk A-S през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

8 ratings

4

Купи

3

Задържане

1

Продай

Техническа оценка

By Trading Central

62.63 / 69.23Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

359 / 380 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.